NCT03528915

Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates

Conjunctivitis Incidence in the Newborn Within the First Week of Life: Impact of the Prophylactic Use of Rifamycine(CRY NOT).

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 881 (actual)
• Sponsor: Centre Hospitalier Universitaire, Amiens · Academic / Other
• Sex: All
• Age: 36 Weeks – 36 Weeks
• Healthy volunteers: Not accepted

Summary

The French guidelines for the use of Rifamycine eye drops in delivery room to prevent neonatal conjunctivitis have been actualized. Only newborns exposed to risk factors of conjunctivitis should be treated, compared to previous guidelines, treating all newborns. currently, there are no data describing risk factors for neonatal conjunctivitis. This study evaluated the incidence of conjunctivitis with or without Rifamycine eye drops treatment in the delivery room. Then risk factors for neonatal conjunctivitis where analyzed.

Conditions

• Ophthalmia Neonatorum

Interventions

Type	Name	Description
OTHER	Rifamycine treatment	Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
OTHER	whithout Rifamycine treatment	Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.

Timeline

• Start date: 2015-09-09
• Primary completion: 2016-05-12
• Completion: 2016-07-24
• First posted: 2018-05-18
• Last updated: 2019-01-23

Locations

1 site across 1 country: France